CRUSHing Lab Fraud: Three Myths that Derail Real Reform

Key Takeaways

• Code stacking inflates genetic test charges up to $8,589 per panel.
• Genetic tests represent 43% ($3.6 B) of Medicare outpatient lab spending.
• Most molecular diagnostics lack proven clinical utility or outcome data.
• Shared billing codes hide performance differences between high‑quality and low‑quality tests.
• Targeted oversight can curb waste without stifling genuine diagnostic innovation.

Pulse Analysis

The CRUSH Request for Information marks a pivotal moment for CMS as it confronts entrenched fraud in the laboratory sector. Recent analyses reveal that laboratories routinely employ "code stacking," billing multiple individual genetic test codes instead of a single panel, inflating reimbursements by thousands of dollars per case. Coupled with ambiguous naming conventions that mask performance disparities, these practices create a fertile environment for systematic overbilling rather than isolated misconduct. By exposing the structural incentives that drive such behavior, the CRUSH initiative sets the stage for data‑driven policy interventions.

Beyond the financial dimension, the clinical value of many genetic and molecular diagnostics remains uncertain. While a subset of tests demonstrably improves diagnosis and guides life‑saving treatment, the majority lack robust evidence of outcome benefit. Yet they now account for 43% of Medicare’s outpatient laboratory spending—roughly $3.6 billion—despite representing only a fraction of total test volume. This mismatch underscores the urgency of tying reimbursement to proven clinical utility at the individual test level, rather than relying on broad category assumptions that can reward low‑evidence, high‑cost offerings.

Industry arguments that tighter oversight will choke innovation overlook the distinction between genuine breakthroughs and volume‑driven proliferation. Requiring transparent test naming, standardized billing codes, and evidence‑based coverage criteria can actually sharpen the competitive landscape, rewarding truly effective diagnostics while weeding out marginal or redundant assays. Such targeted regulation promises to preserve the pipeline of meaningful innovation while safeguarding patients and taxpayers from wasteful, potentially harmful testing practices.